Navigation Links
OncoSec Doses First Patient in Phase II Clinical Trial for Metastatic Melanoma
Date:2/28/2012

SAN DIEGO, Feb. 28, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Investigational Review Board (IRB) approval has been received by the University of California San Francisco and the first patient has been dosed for a Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of advanced stage cutaneous and in-transit metastatic melanoma. UCSF investigators are actively recruiting for this clinical trial.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

"Results from our open-label Phase I study demonstrated that DNA IL-12 and electroporation has the potential to establish a new standard of care for the treatment of late-stage metastatic melanoma," said Punit Dhillon, President and CEO of OncoSec. "With immune response results from this Phase II study expected in the second half of 2012, we are confident this study will validate the value of OMS ElectoImmunotherapy."

A total of up to 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma will be enrolled in this Phase II, single-arm, open-label and multi-center study. The trial is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.

OMS ElectroImmunotherapy utilizes OncoSec's proprietary
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec to Present at World Cancer Immunotherapy Conference
2. OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference
3. OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference
4. OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
5. OncoSec to Present at Medical Device Investor Forum
6. Device Master File for OncoSec Medical System Completed and Submitted to FDA
7. OncoSec Releases Devices for Use in Clinical Trials
8. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
9. OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials
10. OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
11. OncoSec Medical to Present at Industry and Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... , July 21, 2014 /PRNewswire-iReach/ -- Nitrosolution.com, a website ... , will celebrate its first anniversary in August. The ... designed to enhance the body,s ability to produce nitric ... is made up of a variety of phytonutrients and ... been found to increase nitric oxide production ...
(Date:7/21/2014)... YORK , July 21, 2014  EHE International, ... exams with a nationwide physician network, today announced that ... Las Vegas, NV has been named an ... the Las Vegas region now ... help proactively maintain their health. "EHE ...
(Date:7/21/2014)... ALBANY, New York , July 21, 2014 /PRNewswire/ ... market report published by Transparency Market Research "E-Clinical Solution ... and Forecast, 2014 - 2020," the global microfluidic device ... and is expected to grow at a CAGR of ... value of USD 6,515.3 million in 2020. ...
Breaking Medicine Technology:Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 3E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 4E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 5
... Monogram,Biosciences, Inc. (Nasdaq: MGRM ) announced ... Pfizer Inc,s (NYSE: PFE ) phase III ... CCR5-tropic,HIV-1, increased efficacy was shown as a result ... of the enhanced version of Monogram,s Trofile(TM),Assay., ...
... Oct. 26 Paratek Pharmaceuticals, Inc. today,announced positive ... PTK,0796, a first-in-class aminomethylcycline (AMC). The Phase 2 ... (IV) forms of PTK 0796 to,Zyvox(R) in the ... infections (cSSSIs). Paratek,s trial met its primary safety ...
Cached Medicine Technology:Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 2Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 3Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 4Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 5Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 6Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:7/22/2014)... (PRWEB) July 22, 2014 As part ... School of Medicine at Mount Sinai have helped identify ... the risk of developing schizophrenia, in the largest genomic ... with 80,000 people. The findings, published online in Nature, ... schizophrenia, and could lead to new approaches to treating ...
(Date:7/22/2014)... Alan Mozes HealthDay Reporter ... used to treat moderate-to-severe allergic asthma appears to offer relief ... standard medications, new research suggests. The prescription drug -- ... U.S. Food and Drug Administration approval earlier this year for ... is taken at a high dose for a six-month period ...
(Date:7/22/2014)... team has identified protein "signatures" of genetic mutations ... cause of cancer deaths after lung cancer. , ... current issue of the journal Nature ... cancer, "will enable new advances" in diagnosing and ... a first-of-its-kind paper. I think it,s a very ...
(Date:7/22/2014)... 2014 The “Human Insulin Market ... Acting, Premixed), Modern Human Insulin (Rapid Acting, Long ... Novomix, Tresiba, Others) - Forecast to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 For more ... and cold storage consumers with dynamic, specialized ... and customer satisfaction. Offering 50-70% less energy requirements ... process. This process is completed through a non-chemical ... technologies also provide a 4.2 Micron droplet. The ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 3Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 4Health News:Asthma Drug May Help Those With Chronic Hives 2Health News:Asthma Drug May Help Those With Chronic Hives 3Health News:Vanderbilt discovery may advance colorectal cancer diagnosis and treatment 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 5Health News:Smart Fog Inc Announces Cold Storage Humidification Technology to be Exhibited at the 2014 Fresh Summit Convention & Expo 2Health News:Smart Fog Inc Announces Cold Storage Humidification Technology to be Exhibited at the 2014 Fresh Summit Convention & Expo 3
... pioneer and global market leader in acai, with certified ... nationwide from Whole Foods to Publix, Kroger and Safeway, ... false claims by acai scam campaigns and consumer watchdog ... locals for centuries, is a highly nutritious fruit scientifically ...
... in football as it hosts conference chaired by its medical director ... ... Gulf Breeze, FL (Vocus) March 27, 2009 -- The fourth annual ... Orthopaedics & Sports Medicine will attract top physicians, physical therapists ...
... Sky One,Medical, Inc. ("China Sky One Medical" or "the ... pharmaceutical company producing over-the-counter,drugs in the People,s Republic of ... call at 10:30 a.m. Eastern Daylight Time (EDT) on ... fiscal year 2008 financial,results. , ...
... concentrating in areas with high doctor/patient ratios, experts say ... and urban areas of the United States may soon ... for underserved and aging populations, a new study warns. ... areas with already established medical communities, a trend that ...
... School of Medicine have been named Early Career Scientists ... Iannis Aifantis, Ph.D. associate professor of pathology, co-director of ... Institute and Jeremy S. Dasen Ph.D., assistant professor of ... among 50 of the nation,s top scientists being honored ...
... passed today by the Democratically-controlled Michigan House of ... pockets of personal injury lawyers at the expense ... Commerce."By repealing Michigan,s lawsuit abuse protections, the supporters ... becomes a lawsuit magnet," said Wendy Block, Director ...
Cached Medicine News:Health News:Sambazon, World Leader in Acai, Stands up for the Amazonian Fruit's True Nutritional Properties 2Health News:Sambazon, World Leader in Acai, Stands up for the Amazonian Fruit's True Nutritional Properties 3Health News:Catastrophic Head and Neck Injuries Among Focus for NFL Team Physicians and Clinical Staff at Fourth Annual Injuries in Football Conference 2Health News:Catastrophic Head and Neck Injuries Among Focus for NFL Team Physicians and Clinical Staff at Fourth Annual Injuries in Football Conference 3Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss Fourth and Fiscal Year 2008 Results 2Health News:Midwest and Northeast May Face Surgeon Shortage 2Health News:Two NYU Scientists Named Howard Hughes Medical Institute's early career scientists 2Health News:Two NYU Scientists Named Howard Hughes Medical Institute's early career scientists 3